The In Vivo Existence Forms of Engeletin and Their Anti-Hyperuricemia Activity
International Journal of Molecular Sciences · 13.06.2026 · 27 (12) · 5353
DOI: 10.3390/ijms27125353 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.06.2026. Verfasst von Yang Lv und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. Hauptthemen laut MEDLINE: Hyperuricemia, Glycosides, Flavonoids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Smilacis Glabrae Rhizoma is a traditional Chinese medicine commonly used for hyperuricemia. Engeletin, one of its major flavonoids, exhibits various pharmacological activities, but its in vivo uric acid-lowering activity and metabolic processes remain unclear. This study aims to elucidate the in vivo existence forms of engeletin and the pharmacological basis underlying its uric acid-lowering effects. The in vivo metabolites of engeletin were identified by using UHPLC-Q-TOF-MS. The xanthine oxidase inhibitory activity was investigated using in vitro enzymatic assays. The in vivo uric acid-lowering effect was evaluated in hyperuricemic mice. A total of 11, 34, 7, 6, and 5 compounds were detected in urine, feces, serum, liver, and kidney samples, respectively. After removing duplicates, 52 compounds were preliminarily identified as in vivo existence forms of engeletin. The main metabolic reaction types were glucuronidation, sulfation, and hydrolysis. Engeletin exhibited no xanthine oxidase inhibitory activity in vitro but possessed uric acid-lowering activity in vivo. Neoisoastilbin and naringenin were metabolites with both xanthine oxidase inhibitory activity and uric acid-lowering activity. The in vivo uric acid-lowering activity of engeletin may be attributable to its two metabolites rather than itself. This study elucidated the pharmacological basis of engeletin and laid the foundation for developing potential therapeutics for hyperuricemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
- Division of Pharmacognosy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China.
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
- Department of Chemical Biology, Peking University Health Science Center, Beijing 100191, China.
ORCID-Profile: Jing Zhang, Shao-Qing Cai
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lv, Y., Zhang, J., Chen, S. J., Zhang, J., Han, X., Shang, M. Y., Liu, G. X., Wang, X., Cai, S. Q., & Xu, F. (2026). The In Vivo Existence Forms of Engeletin and Their Anti-Hyperuricemia Activity. International Journal of Molecular Sciences, 27(12), 5353. https://doi.org/10.3390/ijms27125353
Vancouver
Lv Y, Zhang J, Chen SJ, Zhang J, Han X, Shang MY, et al. The In Vivo Existence Forms of Engeletin and Their Anti-Hyperuricemia Activity. International Journal of Molecular Sciences. 2026;27(12):5353. doi:10.3390/ijms27125353
BibTeX
@article{Lv2026,
author = {Lv, Yang and Zhang, Jing and Chen, Shao-Jing and Zhang, Jing and Han, Xing and Shang, Ming-Ying and Liu, Guang-Xue and Wang, Xuan and Cai, Shao-Qing and Xu, Feng},
title = {The In Vivo Existence Forms of Engeletin and Their Anti-Hyperuricemia Activity},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {12},
pages = {5353},
doi = {10.3390/ijms27125353}
}
EUVIMED